• Markets
    • icon
  • Companies
OCC · ASX

Orthocell Ltd (ASX:OCC)

AU$0.4

 0.0 (0.0%)
ASX:Live
05/12/2023 04:10:44 PM
HALO Price Momentum HALO Ords HALO Capital Efficiency GROWTH AUS All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

OCC Overview

OCC Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About OCC

Website

Orthocell Ltd

Telephone

61.8.9360.2888

Address

South Street Murdoch University Building 191 Murdoch, Western Australia (WA) 6150

Description

Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. Its products include CelGro which is a naturally derived collagen medical device for soft tissue repair, and Antilogous Tenocyte Implantation (Ortho-ATI) for chronic, treatment resistant tendon injuries. The company was founded by Paul Anderson and Min Hao Zheng on March 21, 2006 and is headquartered in Murdoch, Australia.

OCC Price Chart

Key Stats

Market Cap

AU$77.71M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.32 - 0.46

Trade Value (12mth)

AU$12,676.00

1 week

3.85%

1 month

6.58%

YTD

-1.22%

1 year

-10.99%

All time high

0.99

Key Fundamentals

EPS 3 yr Growth

-11.900%

EBITDA Margin

-229.90%

Operating Cashflow

$15m

Free Cash Flow Return

173.50%

ROIC

-74.30%

Interest Coverage

-319.10

Quick Ratio

5.70

Other Data

Shares on Issue (Fully Dilluted)

197m

HALO Sector

Healthcare

Next Company Report Date

30-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.05

OCC Announcements

Latest Announcements

Date Announcements

31 October 23

AGM Addresses by Chair and Managing Director

×

AGM Addresses by Chair and Managing Director

31 October 23

Results of Annual General Meeting

×

Results of Annual General Meeting

31 October 23

Replacement Constitution

×

Replacement Constitution

31 October 22

Appendix 4C - Quarterly

×

Appendix 4C - Quarterly

31 July 23

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

31 January 22

Appendix 4C - Quarterly

×

Appendix 4C - Quarterly

31 August 23

Appendix 4E & Annual Report

×

Appendix 4E & Annual Report

31 August 23

Corporate Governance Statement

×

Corporate Governance Statement

31 August 23

Appendix 4G

×

Appendix 4G

31 August 22

Final Report and Annual Report to Shareholders

×

Final Report and Annual Report to Shareholders

31 August 22

Appendix 4G

×

Appendix 4G

31 August 20

Appendix 4E and Annual Report to Shareholders

×

Appendix 4E and Annual Report to Shareholders

31 August 18

Preliminary Final Report and Annual Financial Statements

×

Preliminary Final Report and Annual Financial Statements

30 October 23

Proposed issue of securities - OCC

×

Proposed issue of securities - OCC

30 October 23

UWA Royalty Entitlement Exchanged for Shares in Orthocell

×

UWA Royalty Entitlement Exchanged for Shares in Orthocell

30 October 23

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

30 October 23

Cleansing Notice

×

Cleansing Notice

30 November 15

Investor Presentation

×

Investor Presentation

30 January 23

Appendix 4C - Quarterly

×

Appendix 4C - Quarterly

30 December 21

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

30 December 21

Notice under Section 708(A) of the Corporations Act

×

Notice under Section 708(A) of the Corporations Act

30 August 19

Appendix 4E and Annual Report to Shareholders

×

Appendix 4E and Annual Report to Shareholders

29 September 22

OrthoATI Rotator Cuff Study Success With Cross-Over Patients

×

OrthoATI Rotator Cuff Study Success With Cross-Over Patients

29 May 23

John Van Der Wielen appointed Independent Non-Exec Chair

×

John Van Der Wielen appointed Independent Non-Exec Chair

29 May 23

Notification regarding unquoted securities - OCC

×

Notification regarding unquoted securities - OCC

29 May 23

Proposed issue of securities - OCC

×

Proposed issue of securities - OCC

29 March 23

Leading US-based nerve surgeons appointed to advisory board

×

Leading US-based nerve surgeons appointed to advisory board

29 June 22

Notification of cessation of securities - OCC

×

Notification of cessation of securities - OCC

OCC Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.05 -0.03 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.05 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -34.4 3.3 32.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.04 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.03 0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.1 -89.7 61.8 Lock Lock Lock
     Yield % Lock Lock Lock Lock -4.3 -8.6 20.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.09 0.05 0.03 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.08 0.04 0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -21.8 -46.1 -42.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 187 195 197 Lock Lock Lock
Basic m Lock Lock Lock Lock 187 195 197 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 1 2 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 41.5 50.5 177.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 12 12 13 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 1 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 4,786.4 177.6 267.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock 29.5 54.4 72.1 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 71 46 28 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -11 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.0 0.5 12.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,103.5 -729.6 -229.9 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -12 -12 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.2 1.2 10.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,146.3 -752.4 -243.0 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -11 -11 -9 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -2 -3 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -9 -9 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.9 -0.8 31.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -887.8 -594.5 -147.3 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -5 -6 15 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -1 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 1 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -5 -7 14 Lock Lock Lock
     Growth % Lock Lock Lock Lock 9.1 -41.6 306.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -4.7 -4.4 3.3 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 16 11 25 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 19 38 30 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -16 -11 -24 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 28 23 Lock Lock Lock
Equity $m Lock Lock Lock Lock 17 10 6 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 17 10 7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -18.4 -40.8 -36.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -46.8 -24.0 -21.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -53.6 -91.9 -101.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -60.0 -82.6 -120.4 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -46.7 -65.8 -74.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -24.0 -45.3 173.5 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A -319.1 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.4 0.9 2.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -93.1 -106.2 -394.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 8.8 5.2 5.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 8.6 5.1 5.7 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 95.6 31.3 92.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -239.6 -91.8 322.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 3.9 0.1 0.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 2.8 1.3 1.4 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.1 0.1 0.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 87.7 214.3 20.6 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.1 0.0 0.1 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.1 0.0 0.1 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -1,123.0 -734.5 -221.8 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -59.1 -29.7 -31.8 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -46.8 -24.0 -21.1 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 3.8 4.8 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -53.6 -91.9 -101.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -53.6 -91.9 -101.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 131.3 282.5 254.3 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 92.7 2,837.0 1,049.1 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 224.0 3,119.6 1,303.4 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 269.5 902.8 473.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -45.5 2,216.8 830.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.05%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

OCC Shortsell

Frequently Asked Questions

The current share price of Orthocell Ltd (OCC:ASX) is AU$0.4.
The 52-week high share price for Orthocell Ltd (OCC:ASX) is AU$0.46.
The 52-week low share price for Orthocell Ltd (OCC:ASX)? is AU$0.32.
Orthocell Ltd (OCC:ASX) does not pay a dividend.
Orthocell Ltd (OCC:ASX) does not pay a dividend.
Orthocell Ltd (OCC:ASX) does not offer franking credits.
Orthocell Ltd (OCC:ASX) is classified in the Healthcare.
The current P/E ratio for Orthocell Ltd (OCC:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.